Posted inNews and Updates
AstraZeneca Halts Lung Cancer Trial for Bispecific Drug
AstraZeneca halts a key lung cancer trial, determining its bispecific drug cannot outperform Keytruda. Learn about the strategic shift in oncology R&D.
Posted inNews and Updates
FDA Clears ArkBio’s Ziresovir for Severe RSV Phase II Trial
The FDA has approved a Phase II trial for ziresovir, a novel RSV fusion protein inhibitor. Learn how this breakthrough drug targets severe infections.
Posted inNews and Updates
AstraZeneca Halts Phase 3 Lung Cancer Trial: Key Update
AstraZeneca has halted a major Phase 3 lung cancer trial after an independent review found the drug failed to meet primary efficacy goals. Learn more here.
Posted inNews and Updates
TCS Unveils Agentic AI to Accelerate Drug Discovery
TCS has introduced an Agentic AI platform to optimize drug development, using autonomous technology to accelerate discovery and improve clinical success.
Posted inNews and Updates
AI Adoption in Clinical Trials Stagnates at 11%
New data reveals only 11% of sponsors and CROs have fully integrated AI into clinical trials. Discover the barriers to adoption in modern drug development.
Posted inNews and Updates
Clinical Trial Delays and Phase II Failures Rise in 2025
New data reveals a rise in clinical trial site delays and Phase II terminations in 2025. Discover the key factors impacting drug development pipelines.
Posted inNews and Updates
FDA Clears AbelZeta’s Prizlon-cel for B-Cell Lymphoma Trial
AbelZeta receives FDA IND clearance for Prizlon-cel to treat large B-cell lymphoma. Learn how this novel CAR-T therapy could transform oncology care.
Posted inNews and Updates
JW Pharmaceutical Reports Phase 3 Success for Gout Drug
JW Pharmaceutical’s Epaminurad shows superior efficacy in Phase III gout trials, offering a new treatment pathway for patients with chronic hyperuricemia.
Posted inNews and Updates
Metaberine Study: New Findings on Metabolic Health
New clinical research shows Zeus Hygia’s Metaberine® significantly improves metabolic health and glucose markers at a low 200 mg daily dose. Read more.
Posted inNews and Updates
Metaberine Study: New Supplement Improves Metabolic Health
New clinical research shows Metaberine® improves metabolic health and insulin sensitivity with a low 200 mg daily dose. Read the study findings here.